Given the association between HER2 status and the resistance to endocrine treatments, we initially analyzed FOXA1 chromatin interactions in breast cancer cells with varying levels of HER2 (Supplementary Fig. S1A). This evidence concerns the gene ERBB2 and breast carcinoma.